Reata Pharmaceuticals News

RETADelisted Stock  USD 172.36  0.02  0.01%   
About 56% of Reata Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Reata Pharmaceuticals suggests that many traders are alarmed regarding Reata Pharmaceuticals' prospects. Reata Pharmaceuticals' investor sentiment overview provides quick insight into current market opportunities from investing in Reata Pharmaceuticals. The current market sentiment, together with Reata Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Reata Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Reata Pharmaceuticals stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Reata daily returns and investor perception about the current price of Reata Pharmaceuticals as well as its diversification or hedging effects on your existing portfolios.
  
over six months ago at www.macroaxis.com         
Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3
Macroaxis News
over six months ago at news.google.com         
Should You Add Reata Pharmaceuticals to Your Portfolio - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Reata Pharmaceuticals SVP Sold 546K In Company Stock - Reata Pharmaceuticals - Benzinga
Google News at Macroaxis
over six months ago at news.google.com         
Reata Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future - Yahoo Finance
Google News at Macroaxis
over six months ago at news.google.com         
Does Biogens Latest 1.5 Billion-Dollar Move Make It a Buy - Nasdaq
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Wellington Management Group LLP Sells 86,720 Shares of Reata Pharmaceuticals, Inc.
news
over six months ago at thelincolnianonline.com         
Reata Pharmaceuticals Research Coverage Started at StockNews.com
news
over six months ago at news.google.com         
5 Biotech Stocks to Buy as New Drug Approvals Drive Industry Prospects - Yahoo Finance
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
Reata Pharmaceuticals, Inc. Given Consensus Rating of Hold by Analysts
news
over six months ago at thelincolnianonline.com         
Reata Pharmaceuticals, Inc. Stock Holdings Trimmed by Swiss National Bank
news
over six months ago at thelincolnianonline.com         
3,204 Shares in Reata Pharmaceuticals, Inc. Purchased by Pictet Asset Management SA
news
over six months ago at news.google.com         
Better Buy Biogen vs. Eli Lilly - Nasdaq
Google News at Macroaxis
over six months ago at thelincolnianonline.com         
StockNews.com Begins Coverage on Reata Pharmaceuticals
news
over six months ago at thelincolnianonline.com         
Reata Pharmaceuticals Sees Unusually Large Options Volume
news
over six months ago at benzinga.com         
Check Out What Whales Are Doing With RETA
benzinga news
Far too much social signal, news, headlines, and media speculation about Reata Pharmaceuticals that are available to investors today. That information is available publicly through Reata media outlets and privately through word of mouth or via Reata internal channels. However, regardless of the origin, that massive amount of Reata data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Reata Pharmaceuticals news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Reata Pharmaceuticals relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Reata Pharmaceuticals' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Reata Pharmaceuticals alpha.

Reata Pharmaceuticals Performance against NYSE Composite

 Price Growth (%)  
       Timeline  
1
TD Cowen starts Reata at outperform, cites sales potential of ataxia drug
07/06/2023
2
Should you quit your Reata Pharmaceuticals holdings
08/03/2023
3
Entrada Therapeutics, Inc. Reports Q2 Loss, Misses Revenue Estimates
08/08/2023
4
Alimera Sciences Reports Q2 Loss, Lags Revenue Estimates
08/10/2023
5
Sale by Michael Wortley of 807 shares of Reata Pharmaceuticals
08/17/2023
6
Reata Pharmaceuticals, Inc. Stock Holdings Trimmed by Swiss National Bank
08/31/2023
7
Reata Pharmaceuticals, Inc. Is Expected To Breakeven In The Near Future - Yahoo Finance
09/13/2023
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.
You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Consideration for investing in Reata Stock

If you are still planning to invest in Reata Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Reata Pharmaceuticals' history and understand the potential risks before investing.
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm